Patents by Inventor Maria Teresa GOMEZ OCHOA
Maria Teresa GOMEZ OCHOA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404906Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: August 7, 2023Publication date: December 21, 2023Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 11759416Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: January 17, 2022Date of Patent: September 19, 2023Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 11752092Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: November 25, 2020Date of Patent: September 12, 2023Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 11752093Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: February 16, 2022Date of Patent: September 12, 2023Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 11752094Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: May 17, 2022Date of Patent: September 12, 2023Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20220280417Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: May 17, 2022Publication date: September 8, 2022Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20220192972Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: February 16, 2022Publication date: June 23, 2022Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20220133623Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: January 17, 2022Publication date: May 5, 2022Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 11241377Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: October 17, 2019Date of Patent: February 8, 2022Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20210077380Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10881605Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: January 22, 2019Date of Patent: January 5, 2021Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20200085728Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: October 17, 2019Publication date: March 19, 2020Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10463607Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: December 14, 2018Date of Patent: November 5, 2019Assignee: LABORATORIOS FARMACEUTICS ROFI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20190151230Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: January 22, 2019Publication date: May 23, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20190117554Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: December 14, 2018Publication date: April 25, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10195138Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: July 11, 2018Date of Patent: February 5, 2019Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 10182982Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: April 4, 2018Date of Patent: January 22, 2019Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20180318208Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: July 11, 2018Publication date: November 8, 2018Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10085936Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: November 30, 2012Date of Patent: October 2, 2018Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 10058504Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: November 30, 2012Date of Patent: August 28, 2018Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa